The Prolaris® Test: Move Forward With Confidence
Optimal management of clinically localized prostate cancer presents a unique challenge to physicians and patients, because it is a highly variable and often slow-growing, nonaggressive cancer. Prolaris was developed to aid physicians in predicting disease aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris measures the expression level of genes involved with tumor proliferation to predict disease outcome.
In the treatment of prostate cancer Prolaris is prognostic at the point of diagnosis and in the post-surgery setting.
At diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can define patients who appear clinically low-risk but have more aggressive disease that requires more aggressive treatment.
Prolaris testing is also well suited for use in post-prostatectomy patients that have higher risk features after surgery to better estimate their risk of disease recurrence (BCR) and therefore adjust the level of monitoring or add additional therapy.
Prolaris provides unique additional information about a patient’s prognosis and may be used with other clinical factors in helping the healthcare provider make treatment recommendations.
What are the risks?
About 1 in 5 men in Europe receive a diagnosis of prostate cancer in their lifetime. Fortunately, because most prostate cancers are slow-growing and not aggressive, only 3% of men with prostate cancer die from it.8
Is all prostate cancer the same?
While a diagnosis of prostate cancer is alarming, it’s important to know that prostate cancers aren’t all the same. With Prolaris, you have the ability to learn more about the aggressiveness of your specific tumor, so you and your doctor can make a more informed decision about your treatment.5,6
Does PSA and Gleason tell the whole story?
You most likely know your prostate-specific antigen (PSA) level and your Gleason score. These tests tell your doctor how far your cancer has progressed but not necessarily the €œaggressiveness€ of your disease. Since cancer is the uncontrolled rapid growth of abnormal cells, an aggressive prostate tumor carries the potential risk of growing and spreading rapidly to other parts of your body.
What can Prolaris do?
What Prolaris measures is not whether you have prostate cancer, but how fast your cancer cells are dividing, or its aggressiveness. Because all prostate cancers are not the same, getting a Prolaris Score„¢ will tell your doctor additional information about your cancer, which will help in determining its aggressiveness.3,4 This is because Prolaris provides unique information about your cancer that no other test can.
What is Prolaris?
Prolaris is a measure of how fast the cells in your tumor are dividing. Since you have had a biopsy, that tissue sample can be used to determine your Prolaris Score. Studies have shown that Prolaris provides an accurate assessment of cancer aggressiveness.5,6 And, because every individual’s prostate cancer is different, the result of your Prolaris test is unique to you.
Does Prolaris clarify risk?
Two patients with the same PSA and Gleason scores may have a very different estimate of mortality risk when their Prolaris Score is included in their evaluation.
How does Prolaris help me make treatment decisions?
Your Prolaris Score can help you and your doctor make the best treatment decision for you.5,6 For example, if you have a low-risk cancer and a low Prolaris Score, you and your doctor may choose to delay treatment and just monitor it closely. This is called active surveillance. On the other hand, if your Prolaris Score is high, meaning a more aggressive cancer, you and your
doctor may choose to treat your cancer with an aggressive therapy.
After you receive the results of your test, you and your doctor will decide your course of treatment. The added information from the Prolaris Score can allow you to have more confidence in the decisions you make about your medical care.